Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract

Giovanna Angela Giannico, Allen M. Gown, Jonathan Ira Epstein, Frank Revetta, Justin A. Bishop

Research output: Contribution to journalArticle

Abstract

The differential diagnosis of glandular lesions of the bladder/urinary tract can be challenging because of significant morphologic and immunohistochemical overlap between primary lesions and metastasis/direct extension from adjacent organs. Special AT-rich sequence-binding protein 2 (SATB2), encoded on chromosome 2q32-33, is a recently described DNA-binding protein involved in osteoblast lineage commitment and expressed in colorectal and appendiceal neoplasms. In this study, we hypothesized that immunohistochemistry for SATB2 may be of value in distinguishing primary adenocarcinoma of the bladder/urinary tract and urothelial carcinoma with glandular differentiation from gastrointestinal and endocervical primaries. Intensity and distribution of SATB2 nuclear labeling were semiquantitatively scored and compared with those of CDX2. The study included 43 primary adenocarcinomas of the bladder/urinary tract, 20 urothelial carcinomas with glandular differentiation, 26 adenocarcinomas of the uterine cervix, and 22 colorectal adenocarcinomas involving the bladder. Positive SATB2 immunostaining was observed in 21 of 43 (49%) primary bladder/urinary tract adenocarcinomas, in 17 of 22 (77%) colorectal adenocarcinomas, and in the glandular component of 4 of 18 (22%) urothelial carcinomas with glandular differentiation. SATB2 was negative in 25 of 26 endocervical adenocarcinomas and showed focal weak immunostaining (1+) in 1 of 26 (4%). The results were not significantly different from those seen with CDX2. We conclude that SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.

Original languageEnglish (US)
Pages (from-to)152-159
Number of pages8
JournalHuman Pathology
Volume67
DOIs
StatePublished - Sep 1 2017

Fingerprint

AT Rich Sequence
Urinary Tract
Carrier Proteins
Urinary Bladder
Adenocarcinoma
Carcinoma
Appendiceal Neoplasms
Differential Diagnosis
Immunohistochemistry
DNA-Binding Proteins
Osteoblasts
Cervix Uteri
Colorectal Neoplasms
Chromosomes
Neoplasm Metastasis

Keywords

  • CDX2
  • Histologic variants
  • Immunohistochemistry
  • SATB2
  • Urinary bladder
  • Urothelial carcinoma with glandular differentiation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. / Giannico, Giovanna Angela; Gown, Allen M.; Epstein, Jonathan Ira; Revetta, Frank; Bishop, Justin A.

In: Human Pathology, Vol. 67, 01.09.2017, p. 152-159.

Research output: Contribution to journalArticle

Giannico, Giovanna Angela ; Gown, Allen M. ; Epstein, Jonathan Ira ; Revetta, Frank ; Bishop, Justin A. / Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. In: Human Pathology. 2017 ; Vol. 67. pp. 152-159.
@article{6940a20431564563901754bd954fd2ef,
title = "Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract",
abstract = "The differential diagnosis of glandular lesions of the bladder/urinary tract can be challenging because of significant morphologic and immunohistochemical overlap between primary lesions and metastasis/direct extension from adjacent organs. Special AT-rich sequence-binding protein 2 (SATB2), encoded on chromosome 2q32-33, is a recently described DNA-binding protein involved in osteoblast lineage commitment and expressed in colorectal and appendiceal neoplasms. In this study, we hypothesized that immunohistochemistry for SATB2 may be of value in distinguishing primary adenocarcinoma of the bladder/urinary tract and urothelial carcinoma with glandular differentiation from gastrointestinal and endocervical primaries. Intensity and distribution of SATB2 nuclear labeling were semiquantitatively scored and compared with those of CDX2. The study included 43 primary adenocarcinomas of the bladder/urinary tract, 20 urothelial carcinomas with glandular differentiation, 26 adenocarcinomas of the uterine cervix, and 22 colorectal adenocarcinomas involving the bladder. Positive SATB2 immunostaining was observed in 21 of 43 (49{\%}) primary bladder/urinary tract adenocarcinomas, in 17 of 22 (77{\%}) colorectal adenocarcinomas, and in the glandular component of 4 of 18 (22{\%}) urothelial carcinomas with glandular differentiation. SATB2 was negative in 25 of 26 endocervical adenocarcinomas and showed focal weak immunostaining (1+) in 1 of 26 (4{\%}). The results were not significantly different from those seen with CDX2. We conclude that SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.",
keywords = "CDX2, Histologic variants, Immunohistochemistry, SATB2, Urinary bladder, Urothelial carcinoma with glandular differentiation",
author = "Giannico, {Giovanna Angela} and Gown, {Allen M.} and Epstein, {Jonathan Ira} and Frank Revetta and Bishop, {Justin A.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.humpath.2017.07.002",
language = "English (US)",
volume = "67",
pages = "152--159",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract

AU - Giannico, Giovanna Angela

AU - Gown, Allen M.

AU - Epstein, Jonathan Ira

AU - Revetta, Frank

AU - Bishop, Justin A.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The differential diagnosis of glandular lesions of the bladder/urinary tract can be challenging because of significant morphologic and immunohistochemical overlap between primary lesions and metastasis/direct extension from adjacent organs. Special AT-rich sequence-binding protein 2 (SATB2), encoded on chromosome 2q32-33, is a recently described DNA-binding protein involved in osteoblast lineage commitment and expressed in colorectal and appendiceal neoplasms. In this study, we hypothesized that immunohistochemistry for SATB2 may be of value in distinguishing primary adenocarcinoma of the bladder/urinary tract and urothelial carcinoma with glandular differentiation from gastrointestinal and endocervical primaries. Intensity and distribution of SATB2 nuclear labeling were semiquantitatively scored and compared with those of CDX2. The study included 43 primary adenocarcinomas of the bladder/urinary tract, 20 urothelial carcinomas with glandular differentiation, 26 adenocarcinomas of the uterine cervix, and 22 colorectal adenocarcinomas involving the bladder. Positive SATB2 immunostaining was observed in 21 of 43 (49%) primary bladder/urinary tract adenocarcinomas, in 17 of 22 (77%) colorectal adenocarcinomas, and in the glandular component of 4 of 18 (22%) urothelial carcinomas with glandular differentiation. SATB2 was negative in 25 of 26 endocervical adenocarcinomas and showed focal weak immunostaining (1+) in 1 of 26 (4%). The results were not significantly different from those seen with CDX2. We conclude that SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.

AB - The differential diagnosis of glandular lesions of the bladder/urinary tract can be challenging because of significant morphologic and immunohistochemical overlap between primary lesions and metastasis/direct extension from adjacent organs. Special AT-rich sequence-binding protein 2 (SATB2), encoded on chromosome 2q32-33, is a recently described DNA-binding protein involved in osteoblast lineage commitment and expressed in colorectal and appendiceal neoplasms. In this study, we hypothesized that immunohistochemistry for SATB2 may be of value in distinguishing primary adenocarcinoma of the bladder/urinary tract and urothelial carcinoma with glandular differentiation from gastrointestinal and endocervical primaries. Intensity and distribution of SATB2 nuclear labeling were semiquantitatively scored and compared with those of CDX2. The study included 43 primary adenocarcinomas of the bladder/urinary tract, 20 urothelial carcinomas with glandular differentiation, 26 adenocarcinomas of the uterine cervix, and 22 colorectal adenocarcinomas involving the bladder. Positive SATB2 immunostaining was observed in 21 of 43 (49%) primary bladder/urinary tract adenocarcinomas, in 17 of 22 (77%) colorectal adenocarcinomas, and in the glandular component of 4 of 18 (22%) urothelial carcinomas with glandular differentiation. SATB2 was negative in 25 of 26 endocervical adenocarcinomas and showed focal weak immunostaining (1+) in 1 of 26 (4%). The results were not significantly different from those seen with CDX2. We conclude that SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.

KW - CDX2

KW - Histologic variants

KW - Immunohistochemistry

KW - SATB2

KW - Urinary bladder

KW - Urothelial carcinoma with glandular differentiation

UR - http://www.scopus.com/inward/record.url?scp=85028762669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028762669&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2017.07.002

DO - 10.1016/j.humpath.2017.07.002

M3 - Article

VL - 67

SP - 152

EP - 159

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -